Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
The key factors leading to transformed follicular lymphoma (t-FL) include the aberrations of epigenetic modifiers as early and driving events, especially mutations in the gene encoding for histone acetyltransferase. Therefore, reversal of this phenomenon by histone deacetylase (HDAC) inhibitors is e...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/3d713885de444a33b83a276132d8180e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:3d713885de444a33b83a276132d8180e |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:3d713885de444a33b83a276132d8180e2021-12-03T05:09:55ZPreclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma2234-943X10.3389/fonc.2021.780118https://doaj.org/article/3d713885de444a33b83a276132d8180e2021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.780118/fullhttps://doaj.org/toc/2234-943XThe key factors leading to transformed follicular lymphoma (t-FL) include the aberrations of epigenetic modifiers as early and driving events, especially mutations in the gene encoding for histone acetyltransferase. Therefore, reversal of this phenomenon by histone deacetylase (HDAC) inhibitors is essential for the development of new treatment strategies in t-FL. Several t-FL cell lines were treated with various doses of chidamide and subjected to cell proliferation, apoptosis and cell cycle analyses with CCK-8 assay, Annexin V/PI assay and flow cytometry, respectively. Chidamide dose-dependently inhibited cell proliferation, caused G0/G1 cycle arrest and triggered apoptosis in t-FL cells. In addition, the effects of chidamide on tumor growth were evaluated in vivo in xenograft models. RNA-seq analysis revealed gene expression alterations involving the PI3K-AKT signaling pathway might account for the mechanism underlying the antitumor activity of chidamide as a single agent in t-FL. These findings provide a basis for further clinical exploration of chidamide as a promising treatment for FL.Mengya ZhongMengya ZhongJinshui TanJinshui TanGuangchao PanGuangchao PanYuelong JiangYuelong JiangHui ZhouHui ZhouQian LaiQian LaiQinwei ChenQinwei ChenLiyuan FanLiyuan FanManman DengManman DengBing XuBing XuJie ZhaJie ZhaFrontiers Media S.A.articletransformed-follicular lymphoma (t-FL)chidamideHDACPI3K/AKT signalingepigenetic antitumor therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
transformed-follicular lymphoma (t-FL) chidamide HDAC PI3K/AKT signaling epigenetic antitumor therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
transformed-follicular lymphoma (t-FL) chidamide HDAC PI3K/AKT signaling epigenetic antitumor therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Mengya Zhong Mengya Zhong Jinshui Tan Jinshui Tan Guangchao Pan Guangchao Pan Yuelong Jiang Yuelong Jiang Hui Zhou Hui Zhou Qian Lai Qian Lai Qinwei Chen Qinwei Chen Liyuan Fan Liyuan Fan Manman Deng Manman Deng Bing Xu Bing Xu Jie Zha Jie Zha Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma |
| description |
The key factors leading to transformed follicular lymphoma (t-FL) include the aberrations of epigenetic modifiers as early and driving events, especially mutations in the gene encoding for histone acetyltransferase. Therefore, reversal of this phenomenon by histone deacetylase (HDAC) inhibitors is essential for the development of new treatment strategies in t-FL. Several t-FL cell lines were treated with various doses of chidamide and subjected to cell proliferation, apoptosis and cell cycle analyses with CCK-8 assay, Annexin V/PI assay and flow cytometry, respectively. Chidamide dose-dependently inhibited cell proliferation, caused G0/G1 cycle arrest and triggered apoptosis in t-FL cells. In addition, the effects of chidamide on tumor growth were evaluated in vivo in xenograft models. RNA-seq analysis revealed gene expression alterations involving the PI3K-AKT signaling pathway might account for the mechanism underlying the antitumor activity of chidamide as a single agent in t-FL. These findings provide a basis for further clinical exploration of chidamide as a promising treatment for FL. |
| format |
article |
| author |
Mengya Zhong Mengya Zhong Jinshui Tan Jinshui Tan Guangchao Pan Guangchao Pan Yuelong Jiang Yuelong Jiang Hui Zhou Hui Zhou Qian Lai Qian Lai Qinwei Chen Qinwei Chen Liyuan Fan Liyuan Fan Manman Deng Manman Deng Bing Xu Bing Xu Jie Zha Jie Zha |
| author_facet |
Mengya Zhong Mengya Zhong Jinshui Tan Jinshui Tan Guangchao Pan Guangchao Pan Yuelong Jiang Yuelong Jiang Hui Zhou Hui Zhou Qian Lai Qian Lai Qinwei Chen Qinwei Chen Liyuan Fan Liyuan Fan Manman Deng Manman Deng Bing Xu Bing Xu Jie Zha Jie Zha |
| author_sort |
Mengya Zhong |
| title |
Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma |
| title_short |
Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma |
| title_full |
Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma |
| title_fullStr |
Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma |
| title_full_unstemmed |
Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma |
| title_sort |
preclinical evaluation of the hdac inhibitor chidamide in transformed follicular lymphoma |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/3d713885de444a33b83a276132d8180e |
| work_keys_str_mv |
AT mengyazhong preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT mengyazhong preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT jinshuitan preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT jinshuitan preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT guangchaopan preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT guangchaopan preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT yuelongjiang preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT yuelongjiang preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT huizhou preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT huizhou preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT qianlai preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT qianlai preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT qinweichen preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT qinweichen preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT liyuanfan preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT liyuanfan preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT manmandeng preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT manmandeng preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT bingxu preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT bingxu preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT jiezha preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma AT jiezha preclinicalevaluationofthehdacinhibitorchidamideintransformedfollicularlymphoma |
| _version_ |
1718373925268750336 |